Treatment of post transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation

Lancet

Volumn 354, Issue 9191, 1999, Pages 1698-1699

  Cook, Richard C ^a   Connors, Joseph M ^a   Gascoyne, Randy D ^b   Fradet, Guy ^a   Levy, Robert D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CASE REPORT; CLINICAL TRIAL; FEMALE; HUMAN; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REMISSION; SIDE EFFECT;

EID: 0033552425     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02058-9     Document Type: Article

References (5)

1. Magrath I.T., Shad A.T., Sandlund J.T. Lymphoproliferative disorders in immunocompromised individuals. Magrath I.T. The non-Hodgkin's lymphomas. 2nd edn:1997;955-974 Oxford University Press, London.
2. Starzl T.E., Nalesnik M.A., Porter K.A.et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. ii:1984;583-587.
3. Senderowicz A.M., Vitetta E., Headlee D.et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med. 126:1997;882-885.
4. Benekerrou M., Jais J.-P., Leblond V.et al. Anti-B-cell antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 92:1998;3137-3147.
5. Faye A., Abeele T.V.D., Peuchman M., Mathieu-Boue A., Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet. 352:1998;1285.